Scribe Therapeutics Inc. (SCTX)
| Market Cap | 392.26M |
| Revenue (ttm) | 33.30M +86.7% |
| Net Income | -32.30M |
| EPS | -13.18 |
| Shares Out | 18.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 180,843 |
| Open | 20.79 |
| Previous Close | 20.77 |
| Day's Range | 19.73 - 21.95 |
| 52-Week Range | 13.50 - 39.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 57.00 (+175.1%) |
| Est. Earnings | Nov 29, 2026 |
About SCTX
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SCTX stock is "Strong Buy." The 12-month stock price target is $57.0, which is an increase of 175.10% from the latest price.
News
Cathie Wood’s ARK Investment buys 143.3K shares of Scribe Therapeutics today
20:17 EDT Cathie Wood’s ARK Investment buys 143.3K shares of Scribe Therapeutics (SCTX) today
Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72)
Reports Q2 revenue $1.92M, consensus $3.11M. “The second quarter and the weeks immediately following represented a transformational period for Scribe,” said Benjamin Oakes, co-founder and CEO of Scrib...
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting choles...
Scribe Therapeutics Earnings release: Q2 2026
Scribe Therapeutics released its Q2 2026 earnings on September 2, 2026, summarizing the period's financial results.
Scribe Therapeutics Quarterly report: Q2 2026
Scribe Therapeutics has published its Q2 2026 quarterly earnings report on September 2, 2026.
Scribe Therapeutics Slides: Investor presentation
Scribe Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Scribe Therapeutics to Participate in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tec...
Scribe Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Scribe Therapeutics (SCTX) with a Buy rating and $60 price target Scribe is a clinical-stage genetic medicines company developing ELXR epigenetic silencing and XE...
Leerink starts Scribe Therapeutics at Outperform on X-editor platform
As previously reported, Leerink initiated coverage of Scribe Therapeutics (SCTX) with an Outperform rating and $37 price target The firm views Scribe as a “pioneer in the development of safe…
Scribe Therapeutics initiated with an Outperform at Leerink
Leerink analyst David Risinger initiated coverage of Scribe Therapeutics (SCTX) with an Outperform rating and $37 price target
Scribe Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Scribe Therapeutics (SCTX) with a Buy rating and $50 price target The company has developed two proprietary CRISPR platforms for “best-in-class” epigenetic and genetic...
Scribe Therapeutics initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Scribe Therapeutics (SCTX) with an Overweight rating and $60 price target The firm views the company’s ELXR as a “differentiated” epigenetic silencing platform, poten...
Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Goldman Sachs initiated coverage of Scribe Therapeutics (SCTX) with an Early-Stage Biotech rating. It believes STX-1150 “could have best of both world attributes” with siRNA’s reversibility silencing ...
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech...
Opening Day: Scribe Therapeutics makes strong trading debut
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront…
Scribe Therapeutics opens at $25, IPO priced at $15 per share
Scribe Therapeutics (SCTX), which priced 8.58M shares at $15.00, describes itself as a clinical-stage biotechnology company engineering CRISPR-based technologies into “purpose-built in vivo genetic me...
Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share
11:21 EDT Scribe Therapeutics (SCTX) indicated to open at $25, IPO priced at $15 per share
Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share
Scribe Therapeutics (SCTX) priced 8.58M shares at $15.00. Leerink, Goldman Sachs, Guggenheim and Wells Fargo acted as joint book running managers for the offering. Scribe Therapeutics is a clinical-st...
Scribe Therapeutics 8.58M share IPO priced at $15.00
The deal guidance is towards the high-end of the $13.,00-$15.00 range. Leerink, Goldman Sachs, Guggenheim and Wells Fargo acted as joint book running managers for the offering. Published first on…
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech...
Scribe Therapeutics IPO Registration Document (S-1)
Scribe Therapeutics has filed to go public with an IPO on the NASDAQ
Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO
Scribe Therapeutics, a Phase 1 biotech developing CRISPR therapies for cardiovascular diseases, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.